摘要
二茂铁(Ferrocene, Fc)是一类富电子化合物,具有良好的电化学活性,且二茂铁基团具有亲脂性、氧化还原活性、稳定性及低毒性。因此二茂铁的衍生物具有优良的电化学和生物活性,在生物、医学、微生物学等方面已得到广泛应用。PLG是一种小分子三肽,即L-脯氨酸-L-亮氨酸-L-甘氨酸(L-Prolyl-L-Leucyl-Gly-OMe),它又称为促黑激素的抑制激素(Melanocyte stimulating hormone-inhibiting hormone, MIF-1),可抑制黑色素细胞刺激释放因子(Melanocyte Stimulating Hormone, MSH)的释放。大量临床实验证实,PLG可用于治疗帕金森氏症。
以二茂铁甲酸、Pro、Leu、和Gly为起始原料,采用液相合成法,以HBTU和HOBt为缩合剂,将具有电化学活性的二茂铁和具有治疗帕金森氏症的PLG多肽耦联,合成了两种新的二茂铁-肽分子Fc-Pro-Leu-Gly-OMe和Fc-Pro-Leu-Gly-NH2,得到的产物产率分别为：31%,25%。
采用X-ray衍射法在-100℃解析其晶体结构,得到的Fc-PLG-OMe晶体属于单斜晶系,空间点群为C2,晶包参数为：a=20.803(3)A,b=6.4428(4)A,c=20.557(2)A,α=90°,β=115.498(5),γ=90°,Z=4,R=0.0451；两个二茂铁环形成的二面角为178.41(4)°,被取代的二茂铁环与脯氨酸环形成的二面角为14.0°,在甘氨酸的N13和脯氨酸的O11之间形成强烈的氢键(d(N-O)=2.835A)使得整个分子形成一个β-turn的结构。
采用循环伏安法对Fc-PLG在甲醇溶液中的电化学性质进行了检测,氧化峰和还原峰分别为0.475 V和0.392 V,峰电流密度之比为iPa/iPc=1.012,峰电位之差ΔEp=83 mV。并证明了Fc-PLG在甲醇溶液中的电化学行为是一种单电子转移的准可逆过程。
Ferrocene and its derivatives due to their biological activity, high lipophhilicity, redox activity, stability, low cytotoxicity and distinctive electrochemical behavior have been widely used in biology, medicine and microbiology.
PLG (L-Prolyl-L-Leucyl-Gly-OMe) is an endogenous tripeptide found in the central nervous system, it is also known as melanocyte-stimulating release inhibiting factor-1 (MIF-1). It can control the release of melanocyte-stimulating hormone (MSH). A number of clinical studies have showed that PLG possessed substantial therapeutic activities in Parkinson's disease.
Firstly, the ferrocene conjugates Fc-Pro-Leu-Gly-OMe and Fc-Pro-Leu-Gly-NH2 were synthesized from ferrocene, proline, leucine, glysine acid by liquid phase synthesis, using HBTU and HOBt as coupling agents. The structure of the compound was characterized by IR-spectrum, UV-vis spectrum,1H NMR and ESI-MS. Their yields were 31% and 25%.
Secondly, The Fc-PLG crystal structure was analytical at-100℃by diffraction. The crystal was monoclinic, space group C2 with the cell parameter is a=20.803(3) A, b=6.4428(4) A, c=20.557(2) A, a=90°,β=115.498(5)°, y=90°,Z=4, R=0.0451. The twist angle between Cp rings is 178.4°,the amide plane is rotated out of the Cp ring plane by 14.1°. A strong hydrogen bond between the Gly amide nitrogen N13 and Pro amide oxygen is typical for the structure motif of a P-turn. (d(N-O)=2.835A).
A method of CV (Cyclic Voltammetry) was carried out to observe the electrochemical properties of Fc-Pro-Leu-Gly-OMe and it was proved that it was a quasireversible electrochemical process in methanol, the oxidation potential (Ea) and reduction potential (Ec) were observed at 0.475 V and 0.372 V, The oxidation peak shifted about 83 mV to anodic and the ratio of ipa and ipc was 1.012.
引文
[1]Kealy T J, Pauson P L. A new type of organic-iron compound[J]. Nature,1951,168: 1039-1040.
[2]Miller S A. Dicyclopentadienyl iron[J]. Am. Chem. Soc.,1952,74:632-637.
[3]Wilkinson QRosenblum M,Woodward R B,et al.The structure of iron Bis-cyclopentadienyl[J]. Am.Chem.Soc.,1952,74:21-25.
[4]袁耀锋,叶素明,张蕴文,等.具有生物(理)活性的二茂铁衍生物[J].化学通报.1995,5：24-31.
[5]崔小民.二茂铁的合成及应用[J].化学工业与工程技术.2000.30：21-23.
[6]肖陆飞.二茂铁的发现、制备及其应用[J].滁州职业技术学院学报.2009.8：64-70.
[7]Reeves P C. Carboxylation of aromatic compounds:ferrocenecarboxybic acid[J]. Organic Syntheses,1973,56:28-31.
[8]Rosenblum M. Chemistry of iron group[M], Metallocene. John Wiley, N. Y,1965.
[9]山本明夫.有机金属化学[M].北京：科学出版社,1991.
[10]钱延龙,陈新滋.金属有机化学及催化[M].北京：化学工业出版社,1997.
[11]Calleja G, Cerveau G E. Electrochemistry:a tool for characterization of hybrid materials obtaine by non-hydrolytic sol-gel route and containing ferrocene derivatives[J]. Sol-Gel. Sci. Tech.,2003,26:307-310.
[12]Nesmeyanov A N, Bogomolova L G. Synthesisst ructures and biological activity research of novel ferrocenyl[J]. Organomet. Chem.,1972,6(4):61.
[13]Edward E I, Epton R.Synthesis, Structure and antibacterial activities of novel ferrocenyl-containing 1-phenyl-3-ferrocenyl riazolyl aryl-dihydropyrazole derivatives[J]. Organomet. Chem.,1979,168:259.
[14]郭茂林,杨频,杨斌盛.金属茂类化合物抗癌活性及其机理[J],化学通报.1995,3：1-4.
[15]Kopt H, kopf-maier P. Macromolecular ferrocene compounds as cancer drug models[J]. Angew. Chem.,1979,18(6):447.
[16]Eberhard W, Neuse M G, Meirim, et al. Metallocene-containing platinum complexes as potential antitumor agents.1. Dichloro(1,6-differrocenyl-2,5-diazahexane)platinum(II) and cisdichlorobis(1-ferrocenylethylamine)platinum (II)[J]. Organomet.,1988,7:2562-2565.
[17]Houlton A, Roberts R M G, Silver J. Studies on the anti-tumour activity of some iron sandwich compounds[J]. Organomet. Chem.,1991,418:107-111.
[18]Vessieres A, Top S, Pigeon P, et al. Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. generation of antiproliferative effects in vitro[J]. Med. Chem.,2005,48:3937-3940.
[19]Corry A J, Goel A, Alley S R, et al. N-ortho-ferrocenyl benzoyl dipeptide esters: synthesis, structural characterization and in vitro anti-cancer activity of N-{ortho-(ferrocenyl benzoyl}-glycine-L-alanine ethyl ester and N-{ortho-(ferrocenyl)benzoyl}-L-alanine-glycine ethyl ester[J].Organomet. Chem.,2007,6:92-97.
[20]Siden T, Claude C, Jaouen G J. Studies on organometallic selective estrogen receptor modulators. (SERMs) dual activity in the hydroxy-ferrocifen series[J]. Organomet. Chem.,2001,637:500-506.
[21]Dombrowksi K E, Baldwin W. Metallocenes in biochemistry, microbiology & medicine[J]. Organomet.Chem,1986,302:281-306.
[22]Bucci E, Napoli L D, Fabio G D. A new ferrocenemethyl-thymidine nucleoside: Synthesis, incorporation into oligonucleotides and optical spectroscopic studies on the resulting single strand, duplex and triplex structures [J]. Tetrahedron,1999, 55(55):1435-1450.
[23]David R K., Mark A R., Tobin J M.. Design and construction of molecular assemblies with large second-order potical nonlinerities[J]. Quantum chemical aspects. Chem. Rev.,1994,94:195-242.
[24]柴向东,姜月顺,杨文胜.推拉电子取代基对二茂铁衍生物性质及电子结构的影响[J].高等学校化学学报.1996,17：1599.
[25]董绍俊,刘柏峰,毕军.一种新型的化学修饰电极电位传感器[J].科学通报.1984,6：348-351.
[26]Rosenfeld A, Blum J, Gibson D, Ramu A. Preparation, characterization and antileukemic properties of diaminemalonatopatinum(II) complexes tethered to ferrocene[J]. Inorg. Chem. Acta.,1992,201:219-221.
[27]闫美荣,刘庆平,苏秀兰.白细胞酯酶同工酶对胃癌诊断价值的探讨[J].中国组织化学与细胞化学杂志.1996,5：219-221.
[28]陶慰孙,李惟,姜涌明.蛋白质分子基础[M].北京：高等教育出版社,1995.
[29]Atherton E, Sheppard R C. Solid phase peptide synthesis[J]. Oxford University Press,1989.
[30]李越希,黄培堂.多肽在生物医药和诊断试剂中的应用[J].中华生化药物杂志.2001,22：208-210.
[31]唐传核,彭志英.功能性食品基料蛋白质及多肽类开发现状[J].粮食与油脂,2001,36(1)：39-41.
[32]Chen C P, Jeffery D, Jorgenson J W, et al. Sensitive analysis of enkephalin in rat serum by capillary electrophoresis and laser induced fluorecence detetion[J]. J Chrom B:Biomedl. Sci. Appl.,1997,697:149-162.
[33]Hiraoka A, Arato T, Pominaga I, et al. Analysis of low molecular mass protein in cerebrospinal fluid by sodium dodecyl sulfate capillary gel electrophoresis[J]. J Chroma B:Biomed Sci Appl.1997,697:141-147.
[34]Nair R M Q Kastin A J, Schally A V,. Isolation and structure of hypothalamic MSH-release inhibiting hormone[J]. Biochem. Biophys. Res. Commun., 1971,43:1376-1381.
[35]Misshra R K, Singh A N, Johnson R L,et al. L-Prolyl-L-Leucyl-glycinamide (PLG) and its analogs:clinical implications in extrapyramidal motor disorders and depression[J]. Drug. Fut,1986,11:203-207.
[36]Plotnikoff N P, Kastin A J, Anderson M S, et al. DOPA potentiation by MIF[J]. Life. Sci.,1971,10:1279-1383.
[37]Barbeau A. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man[J]. Lancet,1975,683-684.
[38]Kostrzewa R M, Kastin A J, Sabrian S K. Potentiation of apomorphine action in rats by L-prolyl-L-leucyl-glycinamide[J].Pharmacol. Biochem. Behav,1978,9: 375-378.
[39]Plotnikoff N P, Kastin A J. Oxotremorine antagonism by prolyl-leucylglycine amide administered by different routes and with several anticholinergics[J]. Pharmacol. Biochem. Behav.,1974,2:417-419.
[40]Bjorkman S. Sievertsson H. On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use. naunyn schrniedeberg's arch[J]. Pharmacol.,1977,298:79-81.
[41]Chiu S,Mishra R K. Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide[J]. Eur. J. Pharmacol.,1979,53:119-125.
[42]Chiu S, Paulose C S, Mishra R K. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings[J]. Peptides,1981,2:105-111.
[43]Bhargava H N. Binding of 3H-spiroperidol to striatal membranes of rats treated chronically with morphine. influence of Pro-Leu-Gly-NH2 and cyclo (Leu-Gly)[J]. Neuropharma-cology.1983,22:1357-1361.
[44]Chiu P, Rajakumar G, Chiu S, et al. Mesolimbic and striatal dopamine receptor supersensitivity:prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide(PLG) [J]. Peptides,1985,6:179-183.
[45]Bhargava H N. Effects of prolyl-leucyl-glycinamide and cyclo (leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats[J]. Neuropharmacology.1984,23:439-444.
[46]Sheng J G, Xu D L, Tang Q M, et al. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridi(MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1)[J]. Life. Sci.,1987,40:2007-2010.
[47]Creese I, Sibley D R, Hamblin M W,et al. The classification of dopamine receptors:relationship to radioligand binding. Annu[J]. Rev. Neurosci.,1983, 6:43-71.
[48]Kebabian J W, Calne D B. Multiple receptors for dopamine[J]. Nature, 1979,277:93-96.
[49]Cooper D M F, Bier-Laning C M, Halford M K, et al. Dopamine, acting through D2 receptor, inhibits rat striatal adenylate cyclase by a GTP-dependent process[J]. Mol. Pharmacol.,1986,29:113-119.
[50]Lee T, Seeman P, Rajput A, et al. Hornykiewicz 0. Receptor basis for dopaminergic supersensitivity in Parkinson's disease[J].Nature,1978,273:59-61.
[51]Seeman P. Brain dopamine receptors[J]. Pharmacol. Rev.,1980,32:229-313.
[52]Rinne U K, Lonnberg P, Koskinen V. Dopamine receptors in the Parkinsonian brain[J]. Neural. Trans.,1981,17:97-106.
[53]Kostrzewa R M, Kastin A J, Sabrian S K. Potentiation of apomorphine action in rats by L-prolyl-L-leucyl-glycinamide[J]. Pharmacol. Biochem. Behat., 1978,9:375-378.
[54]Smith J, Morgan M. The effect of prolyl-leucyl-glycinamide on drug-induced rotation in lesioned rat[J]. Gen. Pharmacol.,1982,13:203-207.
[55]Bhargava H N. The effect of melanotropin release inhibiting factor, its metabolites and analogs on 3H-spiroperidol and 3H-apomorphine binding sites[J]. Gen. Pharmacol.,1983,14:609-614.
[56]Johnson R L, Rajakumar G, Yu K L, et al. Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity ofthe central dopamine receptor agonist ADTN[J]. Med. Chem.,1986,29:2104-2107.
[57]谭佩幸,陶宗晋等.现代化学试剂手册[M].化学工业出版社,1989.
[58]张厚利,黄姗姗.L-脯氨酸-L-亮氨酸-甘氨酰胺的合成[J].大连医科大报,1999,21(2)：95.
[59]Celis M E, Taleisnik S, Walter R. Regulation of Formation and Proposed Structure of the Factor Inhibiting the Release of Alpha-MSH[J]. Proc. Natl. Acad. Sci.USA.,1971,68:1428-1433.
[60]王集科.帕金森病的治疗进展[J].广西医学,1999,4(21)：123.
[61]赵文新.帕金森病的治疗策略与药物治疗进展[J].中国药房,2007,18(32)：2540.
[62]Regina K, Michael J, Jackson, et al. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets[J]. Movement Disorder,2007,3(22):715-719.
[63]Yu K L, Rajakumar G, Johnron R L, et al. Dopamine receptor modulation by conformationally constrained analogues of Pro-Leu-Gly-NH2[J]. Med. Chem., 1988,31:1430-1436.
[64]Sreenivasan U, Mishra R K, Johnson R L. Synthesis and dopamine receptor modulating activity of lactam conformationally conetrained analogues of Pro-Leu-Gly-NH2[J]. Med. Chem.,1998,96:256-263.
[65]Stivastava L K, Bajwa S B, Johnson R L, et al. Interaction of L-prolyl-L-leucyl-glyinamide with dopamine D2 receptor:evidence for modulation of agonist affinity states in bovine striatal membranes[J]. Neurochem. 1988,50:960-968.
[66]Bhargava H N. Effects of prolyl-leucyl-glycinamide and cyclo-(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats[J]. Neuropharmacology,1984,23:439-444.
[67]Kastin A J, Barbeau A. Preliminary clinical studies with PLG in parkinson's disease[J]. Can. Med. Assoc.J.,1972,107:1079.
[68]Rodney L, Johnson G. Rajakumar, et al. Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN[J].J. Med. Chem,1986,29(10):2105.
[69]Vartak A P, Skoblenick K, Johnson R L. Allosteric modulation of the dopamine receptor by conformationally constrained Type β-turn Peptidominetics of Pro-Leu-Gly-NH2[J]. Med. Chem.,2007,50:6725-6729.
[70]Fisher A, Mann A, Johnson R L. Design and synthesis of photoaffinity-labeling of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor[J]. Med. Chem.,2006,49:307-317.
[71]青凯胜.X-射线衍射分析所需单晶的培养[J].化学工程师.2006,3：4.
[72]张克从,张东穗.晶体生长科学与技术(上)[M].北京：科学出版社.1997,203(204)：217-225.
[73]张克从.近代晶体学基础(上)[M].北京：科学出版社.1987,169(173)：295-298.
[74]钱逸泰.结晶化学导论[M].北京：中国科技大学出版社.1999：344-351.
[75]姚连增.晶体生长基础[M].北京：中国科学技术出版社.1995：25-28,247-249.
[76]Ojima I, Chakravarty S, Dong Q. Antithrombotic agents:from RGD to peptide mimetics[J]. Bioorg. Medchem.,1995,3(4):337-360.
[77]Nonius B V. COLLECT data collection software.1998.
[78]Otwinowski O, Minor W. HKL DENZO and SCALEPACK Processing of X-ray diffraction data collected in oscillation mode[J]. Method. Enzymol.,1997,276: 307-326.
[79]Sheldrick G M. SHELXS-97. Program for the solution of crystal structures[J]. University of Gottingen, Gottingen, Germany,1997.
[80]SHELXTL-NT 6.14, XPREP, Program library for structure solution and molecular graphics,Bruker AXS[J]. Inc.:Madison, WI,2000-2003.
[81]Sheldrick G M. SHELXL97-2. Program for the solution of crystal structures[J]. University of Gottingen, Gottingen, Germany,1997.
[82]Kojima T, Tanaka I, Ashida T. The Structure of tert-butoxycarbonyl-L-prolyl-L-alanylglycimamide[J]. Acta. Cryst.,1982,B38:221-225.
[83]Kamwaya M E, Oster O, Bradaczek H. Structure of tert-butyloxycarbonyl-L-alanyl-L-proline Monohydrate (t-Boc-Ala-Pro)[J]. Acta. Cryst.,1982,38: 172-176.
[84]Sabesan M N, Venkatesan K. Refinement of the crystal structure of tosyl-L-prolyl-L-hydroxyproline monohydrate[J]. Acta. Cryst.,1971,B27:1879-1883.
[85]Ueki T, Bando S, Ashida T, et al. The Structure of o-bromocarboben-zoxy-glycyl-L-prolyl-L-leucyl-glycyl-L-proline ethyl acetate monohydrate:a substrate of the enzyme, collagenase[J]. Acta. Cryst.,1971, B27:2219-2231.
[86]Lin L, Berces A, Kraatz H-B. Ferrocenic acid derivatives:towards rationalizing changes in the electronic and geometric structures[J]. Organomet. Chem., 1998,556:11-20.
[87]Grossel M C, Goldspink M R, Hriljac J A, et al. Metallocene-bridged cryptands.2. Solid-state studies of some ferrocene amides and their cryptand analogs[J]. Organometallics,1991,10:851-860.
[88]Dennis Hall C, Danks L P, Sharpe N W, et al. Crystal structure and solution-state NMR spectra of 1,1'-(1,4,10-trioxa-7,13-diazacyclopentadecane-7,13-diyldicarbonyl) ferrocene hydrate[J]. Organometallics,1990,9:1602-1607.
[89]Cotton F A, Reid A H. Solid-state structure of ferrocenecarboxylic acid, [Fe(C5H4CO2H)(C5H5)][J]. Acta. Cryst.,1985,C41:686-688.
[90]Seiler P, Dunitz J D. The Structure of triclinic ferrocene at 101,123 and 148 K[J].Acta. Cryst.,1979,B35:2020-2032.
[91]Rudko A D, Low B W. The Crystal structure of S-benzyl-L-cysteinyl-L-prolyl-L-leucylglycinamide and its selenium analog[J]. Acta. Cryst.,1975,31: 713-725.
[92]Kraatz H B, Lusztyk J, Enright G D. Ferrocenoyl amino acids:a synthetic and structural study[J]. Inorg. Chem.,1997,36:2400-2405.
[93]Bindra J S, Grodski A, Corey E J. Solid state conformation of the C-terminal tripeptideof oxytocin, L-Pro-L-Leu-Gly-NH2.0.5H2O[J]. Ame. Chem. Sci., 1973,7523-7524.
[94]Janson J C, Ryden L. Protein purification[J]. VCH Publishers,Inc.,1989.